PRME
Prime Medicine, Inc.NASDAQHealthcare$3.32-2.06%ClosedMarket Cap: $599.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.09
P/S
129.41
EV/EBITDA
-3.33
DCF Value
$-0.10
FCF Yield
-27.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-58.1%
Operating Margin
-4498.1%
Net Margin
-4342.4%
ROE
-178.6%
ROA
-58.7%
ROIC
-66.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $838.0K | 4698.2% | $-48.6M | $-46.1M | $-0.26 | — |
| FY 2025 | $4.6M | -58.1% | $-208.3M | $-201.1M | $-1.35 | — |
| Q3 2025 | $1.2M | -3491.0% | $-54.0M | $-50.6M | $-0.32 | — |
| Q2 2025 | $1.1M | -67.2% | $-53.4M | $-52.6M | $-0.41 | — |
| Q1 2025 | $1.5M | 100.0% | $-52.4M | $-51.9M | $-0.40 | — |
| Q4 2024 | $2.2M | 100.0% | $-44.2M | $-42.3M | $-0.36 | — |
| FY 2024 | $3.0M | 100.0% | $-202.5M | $-195.9M | $-1.65 | — |
| Q3 2024 | $209.0K | 100.0% | $-54.2M | $-52.5M | $-0.44 | — |
| Q2 2024 | $0.00 | NaN% | $-55.7M | $-55.3M | $-0.46 | — |
| Q1 2024 | $591.0K | -122.5% | $-48.3M | $-45.8M | $-0.44 | — |
| Q4 2023 | $0.00 | NaN% | $-68.0M | $-65.6M | $-0.67 | — |
| FY 2023 | $0.00 | NaN% | $-204.8M | $-198.1M | $-2.18 | — |